Citation: | ZHANG He-ping, LIU Jia-li, TANG Jin-cheng, XIE Rong, YANG Kun, ZHANG Jie, FENG Jiang-chao. Inhibition of angiotensin Ⅱ type 1 receptor on Renal Fibrosis and Podocyte Damage in AngiotensinⅡ-induced Hypertensive Nephropathy[J]. Journal of Clinical Nephrology, 2022, 22(4): 315-322. DOI: 10.3969/j.issn.1671-2390.2022.04.009 |
[1] |
Rossi GP,Bisogni V,Rossitto G,et al. Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension[J]. High Blood Press Cardiovasc Prev,2020,27(6):547-560. DOI: 10.1007/s40292-020-00415-9.
|
[2] |
Edmonston DL,Sparks MA. Therapeutic options for chronic kidney disease-associated pulmonary hypertension[J]. Curr Opin Nephrol Hypertens,2020,29(5):497-507. DOI:10.1097/MNH. 0000000000000624.
|
[3] |
Georgianos PI,Agarwal R. Resistant hypertension in chronic kidney disease(CKD):prevalence,treatment particularities,and research agenda[J]. Curr Hypertens Rep,2020,22(10):84.DOI: 10.1007/s11906-020-01081-x.
|
[4] |
Hung MH,Huang CC,Chung CM,et al. 24-h ambulatory blood pressure variability and hypertensive nephropathy in Han Chinese hypertensive patients[J]. J Clin Hypertens(Greenwich),2021,23(2):281-288. DOI:10.1111/jch. 14108.
|
[5] |
Exner S,Schuldt C,Sachindra S,et al. AGTR1 is overexpressed in neuroendocrine neoplasms,regulates secretion and may potentially serve as a target for molecular imaging and therapy[J]. Cancers(Basel),2020,12(11):E3138. DOI: 10.3390/cancers12113138.
|
[6] |
Ji LD,Li JY,Yao BB,et al. Are genetic polymorphisms in the renin-angiotensin-aldosterone system associated with essential hypertension? Evidence from genome-wide association studies[J]. J Hum Hypertens,2017,31(11):695-698. DOI:10.1038/jhh. 2017.29.
|
[7] |
Demirgan EB,Saygili S,Canpolat N,et al. AGTR1-related renal tubular dysgeneses may not be fatal[J]. Kidney Int Rep,2020,6(3):846-852. DOI:10.1016/j. ekir. 2020.11.033.
|
[8] |
陈建,曾莉,陈刚,等.单侧肾切除及微渗透泵灌注血管紧张素Ⅱ诱导小鼠肾纤维化与高血压模型的建立[J].中国比较医学杂志,2015,25(2):26-29,37,85. DOI:10.3969. j. issn. 1671.7856.2015.002.007.
Chen J,Zeng L,Chen G,et al. Establishment of a mouse model of renal fibrosis and hypertension induced by unilateral nephrectomy and infusion of angiotensinⅡusing a micro-osmotic pump[J]. Chin J Comp Med,2015,25(2):26-29,37,85. DOI:10.3969. j. issn. 1671.7856.2015.002.007.
|
[9] |
吕海永,全春花.中西医治疗高血压肾病的研究进展[J].吉林医学,2020,41(4):956-958. DOI:10.3969/j. issn. 1004-0412.2020.04.089.
Lyu HY,Quan CH. Research progress on treatment of hypertensive nephropathy with traditional Chinese and western medicine[J]. Jilin Med J,2020,41(4):956-958. DOI:10.3969/j. issn.1004-0412.2020.04.089.
|
[10] |
Haznedaroglu IC,Malkan UY. Local bone marrow reninangiotensin system in the genesis of leukemia and other malignancies[J]. Eur Rev Med Pharmacol Sci,2016,20(19):4089-4111.
|
[11] |
Escobales N,Nuñez RE,Javadov S. Mitochondrial angiotensin receptors and cardioprotective pathways[J]. Am J Physiol Heart Circ Physiol,2019,316(6):H1426-H1438. DOI:10.1152/ajpheart. 00772.2018.
|
[12] |
Pahlavani M,Kalupahana NS,Ramalingam L,et al. Regulation and functions of the renin-angiotensin system in white and brown adipose tissue[J]. Compr Physiol,2017,7(4):1137-1150.DOI:10.1002/cphy. c160031.
|
[13] |
Zhuang Y,Niu FK,Liu DF,et al. Association between AGTR1A1166C polymorphism and the susceptibility to diabetic nephropathy:evidence from a meta-analysis[J]. Medicine(Baltimore),2018,97(41):e07689. DOI:10.1097/MD. 0000000000007689.
|
[14] |
Baniamerian H,Bahrehmand F,Vaisi-Raygani A,et al. Angiotensin type 1 receptor A1166C polymorphism and systemic lupus erythematosus:correlation with cellular immunity and oxidative stress markers[J]. Lupus,2017,26(14):1534-1539. DOI: 10.1177/0961203317711008.
|
[15] |
Coulson R,Liew SH,Connelly AA,et al. The angiotensin receptor blocker,Losartan,inhibits mammary tumor development and progression to invasive carcinoma[J]. Oncotarget,2017,8(12):18640-18656. DOI:10.18632/oncotarget. 15553.
|
[16] |
Park JW,Kim KA,Kim YI,et al. Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings[J]. Basic Clin Pharmacol Toxicol,2019,125(4):345-352. DOI:10.1111/bcpt. 13244.
|
[17] |
Wang CS,Boyd R,Mitchell R,et al. Development of a novel mobile application to detect urine protein for nephrotic syndrome disease monitoring[J]. BMC Med Inform Decis Mak,2019,19(1):105. DOI: 10.1186/s12911-019-0822-z.
|
[18] |
Gao X,Suo YH,Zhang M,et al. Angiopoietin-like protein 3markedly enhanced in the hyperlipidemia related proteinuria[J].Lipids Health Dis,2019,18(1):116. DOI: 10.1186/s12944-019-1052-1.
|
[19] |
谢志勇,李志莲,董伟,等.慢性肾小球疾病谱演变和膜性肾病流行病学特点[J].临床肾脏病杂志,2019,19(7):471-476,492.DOI:10.3969/j. issn. 1671-2390.2019.07.001.
Xie ZY,Li ZL,Dong W,et al. Evolution of chronic glomerular disease spectrum and epidemiological characteristics of membranous nephropathy[J]. J Clin Nephrol,2019,19(7):471-476,492.DOI:10.3969/j. issn. 1671-2390.2019.07.001.
|
[20] |
Kravets I,Mallipattu SK. The role of podocytes and podocyteassociated biomarkers in diagnosis and treatment of diabetic kidney disease[J]. J Endocr Soc,2020,4(4):bvaa029. DOI: 10.1210/jendso/bvaa029.
|
[21] |
Ornellas FM,Ramalho RJ,Fanelli C,et al. Mesenchymal stromal cells induce podocyte protection in the puromycin injury model[J]. Sci Rep,2019,9(1):19604. DOI: 10.1038/s41598-019-55284-7.
|
[22] |
Humphreys BD. Mechanisms of renal fibrosis[J]. Annu Rev Physiol,2018,80:309-326. DOI: 10.1146/annurev-physiol-022516-034227.
|
[23] |
赵雪谦,刘云启,杨敏.肾纤维化相关生长因子研究新进展[J].临床肾脏病杂志,2017,17(3):181-184. DOI:10.3969/j. issn.1671-2390.2017.03.011.
Zhao XQ,Liu YQ,Yang M. Research progress of renal fibrosisrelated growth factors[J]. J Clin Nephrol,2017,17(3):181-184.DOI:10.3969/j. issn. 1671-2390.2017.03.011.
|